Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity
Selective S1P receptor modulation with ozanimod affects the CXCL13:CXCR5 axis by reducing circulating CXCR5<sup>+</sup> lymphocytes and serum CXCL13, which may contribute to reduce meningeal inflammation in MS. Moreover, the anti-SARS-CoV-2 immune defense appeared to be preserved during treatment with SARS-CoV-2-reactive CD8<sup>+</sup> T cells, possibly compensating the lack of CD4<sup>+</sup> T cell responses. Our immunological data may well apply to other viral infections and underscore the favorable safety and efficacy profile of ozanimod.
Authors
- Ferdinand Otto (ORCID: https://orcid.org/0000-0003-1568-089X)
- Richard Friedrich Radlberger (ORCID: https://orcid.org/0000-0002-5704-9097)
- Peter Wipfler (ORCID: https://orcid.org/0000-0003-4982-4855)
- Hannes Oberkofler
- Andrea Harrer (ORCID: https://orcid.org/0000-0001-7717-6125)
- Karolin Thiel (ORCID: https://orcid.org/0000-0002-7328-7589)
- Tobias Moser (ORCID: https://orcid.org/0000-0002-5397-5595)
- Barbara A. Slade
- Beate Buchegger
- Thomas Haybaeck
Institutions
- Paracelsus Medical University (AT)
- University Hospital of Zurich (CH)
- Christian Doppler Klinik (AT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s40120-025-00831-w
- Citations
- 1
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.81